Edesa biotech, inc. (SBOT)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Aug'14Jun'14Mar'14Dec'13
Net loss

0

0

-

-

-3,179

-4,003

-5,038

-5,130

-5,194

-4,945

-5,030

-5,150

-5,124

-4,881

-5,026

-5,222

-3,564

-3,129

-2,843

-6,142

-3,198

-4,205

-8,439

0

0

0

Adjustments for:
Depreciation

9

7

5

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Straight-line operating lease expense

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

-

-

-

-

-

-

-

-

-

178

171

162

149

146

150

154

159

157

156

164

158

0

0

0

Share-based compensation

410

43

46

123

85

145

154

90

144

99

115

142

156

171

259

232

235

304

267

430

541

574

956

0

0

0

Foreign exchange (gain) loss

-

-

-

-

-

-

-35

92

170

221

162

-10

-82

108

76

-152

-67

-601

-653

-561

-492

-367

-222

0

0

0

(Gain) loss in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-211

-536

717

1,779

2,131

-911

2,362

1,486

-2,533

0

0

0

Transfer equipment to research and development

-

-

-

-

-

-

12

12

12

10

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Change in equity investment in joint venture

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in working capital items:
Accounts and other receivable

-156

-118

-12

148

-5

27

40

-4

-3

-2

-84

2

55

-22

-71

-103

-6

0

113

111

-60

-129

-121

0

0

0

Prepaid expenses and other assets

269

185

305

278

-114

-78

-36

-253

-166

-208

-235

198

180

139

197

-130

53

149

45

126

92

60

94

0

0

0

Inventory

-

-

-

-

-

0

156

96

-105

-211

-181

-427

-232

-198

-307

374

408

393

522

159

100

257

0

0

0

0

Accounts payable and accrued liabilities

-1,957

-1,707

-1,921

-1,453

15

-119

172

144

156

-27

-302

-240

-9

-121

-33

297

31

177

77

119

131

140

106

0

0

0

Operating lease liabilities

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-86

86

101

-71

15

15

0

0

0

Net cash used in operating activities

-6,407

-5,635

-5,228

-6,684

-2,863

-3,853

-4,615

-2,949

-4,591

-4,479

-4,699

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Proceeds on sales of property and equipment

79

59

36

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-4,301

-

-4,103

-4,287

-4,465

-4,266

0

0

0

Purchase of property and equipment

-

-

-333

2

178

6

382

144

381

253

302

307

265

311

402

366

480

410

274

203

86

108

279

0

0

0

Purchase of short-term investments

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of short-term investments

-

-

-

-

-

-

9,083

7,965

3,505

5,004

5,005

8,998

11,995

11,998

11,995

6,006

2,012

14

13

0

0

0

-

-

-

0

Proceeds on sales and maturities of short-term investments

-

-

-

-

-

-

5,000

6,500

7,000

8,000

7,000

0

0

0

-

-

-

-

410

419

424

442

0

0

0

0

Net cash provided by (used in) investing activities

6,461

5,940

6,417

984

-5,756

-5,427

-4,466

2,855

3,112

2,741

1,691

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Payments for issuance costs

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-457

-

-5,263

-5,134

-5,133

-5,745

0

0

0

Proceeds from common shares subscribed

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,368

1,446

1,446

1,446

106

1,374

1,374

1,779

4,308

0

0

0

Net cash provided by financing activities

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

1

109

110

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1,446

-

7,853

7,853

8,258

10,787

0

0

0

Effect of exchange rate changes on cash and cash equivalents

-

-

-

-

-

-

-35

92

170

221

162

-4

-78

104

96

-150

-58

-561

-629

-508

-445

-351

-212

0

0

0

Net change in cash and cash equivalents

3,947

459

1,300

3,551

244

-507

-345

-340

-1,308

-1,515

-2,845

-1,139

-1,360

1,997

3,461

-360

-175

-3,873

-4,812

-2,022

-2,014

-1,691

563

0

0

0

Supplemental disclosure of non-cash financing activities
Cash paid during the period for taxes

-

-

-

-

-

-

0

0

0

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-